NeuroPace, Inc. (NPCE): Price and Financial Metrics

NeuroPace, Inc. (NPCE): $4.50

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NPCE Price/Volume Stats

Current price $4.50 52-week high $6.50
Prev. close $4.50 52-week low $1.22
Day low $4.35 Volume 7,600
Day high $4.53 Avg. volume 25,606
50-day MA $4.53 Dividend yield N/A
200-day MA $3.55 Market Cap 114.32M

NPCE Stock Price Chart Interactive Chart >

NPCE Stock Summary

  • NEUROPACE INC's market capitalization of $114,705,209 is ahead of only 22.94% of US-listed equities.
  • NPCE's went public 2.09 years ago, making it older than merely 6.98% of listed US stocks we're tracking.
  • The volatility of NEUROPACE INC's share price is greater than that of 87.15% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to NEUROPACE INC, a group of peers worth examining would be MASS, MMAT, BASE, LEDS, and MOMO.
  • NPCE's SEC filings can be seen here. And to visit NEUROPACE INC's official web site, go to www.neuropace.com.

NPCE Valuation Summary

  • In comparison to the median Healthcare stock, NPCE's price/sales ratio is 9.09% higher, now standing at 2.4.
  • NPCE's EV/EBIT ratio has moved up 40.8 over the prior 25 months.

Below are key valuation metrics over time for NPCE.

Stock Date P/S P/B P/E EV/EBIT
NPCE 2023-05-23 2.4 4.2 -2.5 -4.6
NPCE 2023-05-22 2.4 4.3 -2.6 -4.7
NPCE 2023-05-19 2.4 4.2 -2.5 -4.6
NPCE 2023-05-18 2.2 3.9 -2.3 -4.5
NPCE 2023-05-17 2.2 4.0 -2.4 -4.5
NPCE 2023-05-16 2.2 3.9 -2.4 -4.5

NPCE Price Target

For more insight on analysts targets of NPCE, see our NPCE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.50 Average Broker Recommendation 1.3 (Strong Buy)

NeuroPace, Inc. (NPCE) Company Bio


NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.


NPCE Latest News Stream


Event/Time News Detail
Loading, please wait...

NPCE Latest Social Stream


Loading social stream, please wait...

View Full NPCE Social Stream

Latest NPCE News From Around the Web

Below are the latest news stories about NEUROPACE INC that investors may wish to consider to help them evaluate NPCE as an investment opportunity.

Q1 2023 Neuropace Inc Earnings Call

Q1 2023 Neuropace Inc Earnings Call

Yahoo | May 5, 2023

NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

First quarter 2023 revenue increased 27% year-over-year to $14.5 million Full-year revenue guidance updated on strength of first quarter performance. Now expected to be $52-$54 million, up from $50-$52 million MOUNTAIN VIEW, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2023. Recent Highlights

Yahoo | May 4, 2023

NeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023

MOUNTAIN VIEW, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2023 after market close on Thursday, May 4, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the confe

Yahoo | April 17, 2023

Further Upside For NeuroPace, Inc. (NASDAQ:NPCE) Shares Could Introduce Price Risks After 39% Bounce

Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 39% in the...

Yahoo | April 17, 2023

NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare Conference

MOUNTAIN VIEW, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 22nd Annual Needham Virtual Healthcare Conference. Management is scheduled to present on Monday, April 17th, 2023 at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live webcast of this event, as well as an archived recording, will be availa

Yahoo | April 3, 2023

Read More 'NPCE' Stories Here

NPCE Price Returns

1-mo -10.00%
3-mo -12.28%
6-mo 179.50%
1-year -27.77%
3-year N/A
5-year N/A
YTD 202.01%
2022 -85.22%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8379 seconds.